Literature DB >> 30508377

Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using 64Cu-Labeled Macrin.

Hye-Yeong Kim1,2, Ran Li1, Thomas S C Ng1, Gabriel Courties1, Christopher Blake Rodell1, Mark Prytyskach1, Rainer H Kohler1, Mikael J Pittet1,2, Matthias Nahrendorf1,2, Ralph Weissleder1,2,3, Miles A Miller1,2.   

Abstract

Tumor-associated macrophages (TAMs) are widely implicated in cancer progression, and TAM levels can influence drug responses, particularly to immunotherapy and nanomedicines. However, it has been difficult to quantify total TAM numbers and their dynamic spatiotemporal distribution in a non-invasive and translationally relevant manner. Here, we address this need by developing a pharmacokinetically optimized, 64Cu-labeled polyglucose nanoparticle (Macrin) for quantitative positron emission tomography (PET) imaging of macrophages in tumors. By combining PET with high-resolution in vivo confocal microscopy and ex vivo imaging of optically cleared tissue, we found that Macrin was taken up by macrophages with >90% selectivity. Uptake correlated with the content of macrophages in both healthy tissue and tumors ( R2 > 0.9) and showed striking heterogeneity in the TAM content of an orthotopic and immunocompetent mouse model of lung carcinoma. In a proof-of-principle application, we imaged Macrin to monitor the macrophage response to neo-adjuvant therapy, using a panel of chemotherapeutic and γ-irradiation regimens. Multiple treatments elicited 180-650% increase in TAMs. Imaging identified especially TAM-rich tumors thought to exhibit enhanced permeability and retention of nanotherapeutics. Indeed, these TAM-rich tumors accumulated >700% higher amounts of a model poly(d,l-lactic- co-glycolic acid)- b-polyethylene glycol (PLGA-PEG) therapeutic nanoparticle compared to TAM-deficient tumors, suggesting that imaging may guide patient selection into nanomedicine trials. In an orthotopic breast cancer model, chemoradiation enhanced TAM and Macrin accumulation in tumors, which corresponded to the improved delivery and efficacy of two model nanotherapies, PEGylated liposomal doxorubicin and a TAM-targeted nanoformulation of the toll-like receptor 7/8 agonist resiquimod (R848). Thus, Macrin imaging offers a selective and translational means to quantify TAMs and inform therapeutic decisions.

Entities:  

Keywords:  EPR effect; immunogenic chemotherapy; myeloid infiltration; personalized medicine; prognostic biomarker; tumor microenvironment

Mesh:

Substances:

Year:  2018        PMID: 30508377      PMCID: PMC6482841          DOI: 10.1021/acsnano.8b04338

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  60 in total

1.  Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.

Authors:  Felix Klug; Hridayesh Prakash; Peter E Huber; Tobias Seibel; Noemi Bender; Niels Halama; Christina Pfirschke; Ralf Holger Voss; Carmen Timke; Ludmila Umansky; Kay Klapproth; Knut Schäkel; Natalio Garbi; Dirk Jäger; Jürgen Weitz; Hubertus Schmitz-Winnenthal; Günter J Hämmerling; Philipp Beckhove
Journal:  Cancer Cell       Date:  2013-10-24       Impact factor: 31.743

2.  Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

Authors:  Timothy M Nywening; Andrea Wang-Gillam; Dominic E Sanford; Brian A Belt; Roheena Z Panni; Brian M Cusworth; Adetunji T Toriola; Rebecca K Nieman; Lori A Worley; Motoyo Yano; Kathryn J Fowler; A Craig Lockhart; Rama Suresh; Benjamin R Tan; Kian-Huat Lim; Ryan C Fields; Steven M Strasberg; William G Hawkins; David G DeNardo; S Peter Goedegebuure; David C Linehan
Journal:  Lancet Oncol       Date:  2016-04-04       Impact factor: 41.316

3.  Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma.

Authors:  Miriam Benezra; Oula Penate-Medina; Pat B Zanzonico; David Schaer; Hooisweng Ow; Andrew Burns; Elisa DeStanchina; Valerie Longo; Erik Herz; Srikant Iyer; Jedd Wolchok; Steven M Larson; Ulrich Wiesner; Michelle S Bradbury
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

4.  Imaging the emergence and natural progression of spontaneous autoimmune diabetes.

Authors:  James F Mohan; Rainer H Kohler; Jonathan A Hill; Ralph Weissleder; Diane Mathis; Christophe Benoist
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-24       Impact factor: 11.205

5.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.

Authors:  Christina Pfirschke; Camilla Engblom; Steffen Rickelt; Virna Cortez-Retamozo; Christopher Garris; Ferdinando Pucci; Takahiro Yamazaki; Vichnou Poirier-Colame; Andita Newton; Younes Redouane; Yi-Jang Lin; Gregory Wojtkiewicz; Yoshiko Iwamoto; Mari Mino-Kenudson; Tiffany G Huynh; Richard O Hynes; Gordon J Freeman; Guido Kroemer; Laurence Zitvogel; Ralph Weissleder; Mikael J Pittet
Journal:  Immunity       Date:  2016-02-09       Impact factor: 31.745

6.  Software for quantification of labeled bacteria from digital microscope images by automated image analysis.

Authors:  Jyrki Selinummi; Jenni Seppälä; Olli Yli-Harja; Jaakko A Puhakka
Journal:  Biotechniques       Date:  2005-12       Impact factor: 1.993

7.  Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts.

Authors:  Miles A Miller; Ravi Chandra; Michael F Cuccarese; Christina Pfirschke; Camilla Engblom; Shawn Stapleton; Utsarga Adhikary; Rainer H Kohler; James F Mohan; Mikael J Pittet; Ralph Weissleder
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

Review 8.  The role of myeloid cells in cancer therapies.

Authors:  Camilla Engblom; Christina Pfirschke; Mikael J Pittet
Journal:  Nat Rev Cancer       Date:  2016-07       Impact factor: 60.716

9.  Therapeutic siRNA silencing in inflammatory monocytes in mice.

Authors:  Florian Leuschner; Partha Dutta; Rostic Gorbatov; Tatiana I Novobrantseva; Jessica S Donahoe; Gabriel Courties; Kang Mi Lee; James I Kim; James F Markmann; Brett Marinelli; Peter Panizzi; Won Woo Lee; Yoshiko Iwamoto; Stuart Milstein; Hila Epstein-Barash; William Cantley; Jamie Wong; Virna Cortez-Retamozo; Andita Newton; Kevin Love; Peter Libby; Mikael J Pittet; Filip K Swirski; Victor Koteliansky; Robert Langer; Ralph Weissleder; Daniel G Anderson; Matthias Nahrendorf
Journal:  Nat Biotechnol       Date:  2011-10-09       Impact factor: 54.908

10.  The Immune Landscape of Cancer.

Authors:  Vésteinn Thorsson; David L Gibbs; Scott D Brown; Denise Wolf; Dante S Bortone; Tai-Hsien Ou Yang; Eduard Porta-Pardo; Galen F Gao; Christopher L Plaisier; James A Eddy; Elad Ziv; Aedin C Culhane; Evan O Paull; I K Ashok Sivakumar; Andrew J Gentles; Raunaq Malhotra; Farshad Farshidfar; Antonio Colaprico; Joel S Parker; Lisle E Mose; Nam Sy Vo; Jianfang Liu; Yuexin Liu; Janet Rader; Varsha Dhankani; Sheila M Reynolds; Reanne Bowlby; Andrea Califano; Andrew D Cherniack; Dimitris Anastassiou; Davide Bedognetti; Younes Mokrab; Aaron M Newman; Arvind Rao; Ken Chen; Alexander Krasnitz; Hai Hu; Tathiane M Malta; Houtan Noushmehr; Chandra Sekhar Pedamallu; Susan Bullman; Akinyemi I Ojesina; Andrew Lamb; Wanding Zhou; Hui Shen; Toni K Choueiri; John N Weinstein; Justin Guinney; Joel Saltz; Robert A Holt; Charles S Rabkin; Alexander J Lazar; Jonathan S Serody; Elizabeth G Demicco; Mary L Disis; Benjamin G Vincent; Ilya Shmulevich
Journal:  Immunity       Date:  2018-04-05       Impact factor: 43.474

View more
  38 in total

1.  Single-Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics.

Authors:  Ran Li; Adel Attari; Mark Prytyskach; Michelle A Garlin; Ralph Weissleder; Miles A Miller
Journal:  Cytometry A       Date:  2019-08-19       Impact factor: 4.355

Review 2.  Enhancing cancer immunotherapy with nanomedicine.

Authors:  Darrell J Irvine; Eric L Dane
Journal:  Nat Rev Immunol       Date:  2020-01-31       Impact factor: 53.106

3.  Combining Nanomedicine and Immunotherapy.

Authors:  Yang Shi; Twan Lammers
Journal:  Acc Chem Res       Date:  2019-05-23       Impact factor: 22.384

4.  Imaging Cardiovascular and Lung Macrophages With the Positron Emission Tomography Sensor 64Cu-Macrin in Mice, Rabbits, and Pigs.

Authors:  Matthias Nahrendorf; Friedrich Felix Hoyer; Anu E Meerwaldt; Mandy M T van Leent; Max L Senders; Claudia Calcagno; Philip M Robson; George Soultanidis; Carlos Pérez-Medina; Abraham J P Teunissen; Yohana C Toner; Kiyotake Ishikawa; Kenneth Fish; Ken Sakurai; Esther M van Leeuwen; Emma D Klein; Alexandros Marios Sofias; Thomas Reiner; David Rohde; Aaron D Aguirre; Gregory Wojtkiewicz; Stephen Schmidt; Yoshiko Iwamoto; David Izquierdo-Garcia; Peter Caravan; Filip K Swirski; Ralph Weissleder; Willem J M Mulder
Journal:  Circ Cardiovasc Imaging       Date:  2020-10-20       Impact factor: 7.792

5.  A Supramolecular Nanocarrier for Delivery of Amiodarone Anti-Arrhythmic Therapy to the Heart.

Authors:  Maaz S Ahmed; Christopher B Rodell; Maarten Hulsmans; Rainer H Kohler; Aaron D Aguirre; Matthias Nahrendorf; Ralph Weissleder
Journal:  Bioconjug Chem       Date:  2019-01-18       Impact factor: 4.774

Review 6.  The expanding landscape of inflammatory cells affecting cancer therapy.

Authors:  Ralph Weissleder; Mikael J Pittet
Journal:  Nat Biomed Eng       Date:  2020-03-18       Impact factor: 25.671

7.  Myeloid Cell-Targeted Nanocarriers Efficiently Inhibit Cellular Inhibitor of Apoptosis for Cancer Immunotherapy.

Authors:  Peter D Koch; Christopher B Rodell; Rainer H Kohler; Mikael J Pittet; Ralph Weissleder
Journal:  Cell Chem Biol       Date:  2020-01-02       Impact factor: 8.116

8.  Metallofluorocarbon Nanoemulsion for Inflammatory Macrophage Detection via PET and MRI.

Authors:  Chao Wang; Benjamin I Leach; Deanne Lister; Stephen R Adams; Hongyan Xu; Carl Hoh; Patrick McConville; Jing Zhang; Karen Messer; Eric T Ahrens
Journal:  J Nucl Med       Date:  2020-12-04       Impact factor: 10.057

9.  Imaging the Immune Tumor Microenvironment to Monitor and Improve Therapy.

Authors:  Gary D Luker
Journal:  Radiology       Date:  2020-10-27       Impact factor: 11.105

10.  Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer.

Authors:  Thomas S C Ng; Viswanath Gunda; Ran Li; Mark Prytyskach; Yoshiko Iwamoto; Rainer H Kohler; Sareh Parangi; Ralph Weissleder; Miles A Miller
Journal:  Radiology       Date:  2020-10-27       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.